Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Operating Expenses

The Total Operating Expenses of Shanghai Rendu Biotechnology Co (688193.SS) as of Oct 28, 2026 is 85.03 M CNY. In the previous year, Total Operating Expenses was 96.76 M CNY — a change of -12.12% (lower).

Operating Expenses

85.03 MCNY

YoY

-12.12%

Last updated:

Total Operating Expenses of Shanghai Rendu Biotechnology Co is 2025 85.03 M CNY. Total Operating Expenses of Shanghai Rendu Biotechnology Co was 2024 96.76 M CNY. It decreases by -12.12% lower compared to the previous year.

The Shanghai Rendu Biotechnology Co Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
92.53 M CNY
Jan 1, 2019
79.50 M CNY
Jan 1, 2020
114.07 M CNY
Jan 1, 2021
90.46 M CNY
Jan 1, 2022
110.55 M CNY
Jan 1, 2023
93.50 M CNY
Jan 1, 2024
96.76 M CNY
Jan 1, 2025
85.03 M CNY
The Shanghai Rendu Biotechnology Co Operating Expenses history
YEAROperating ExpensesYoY
85.03 MCNY-12.12%
96.76 MCNY+3.49%
93.50 MCNY-15.42%
110.55 MCNY+22.21%
90.46 MCNY-20.70%
114.07 MCNY+43.48%
79.50 MCNY-14.08%
92.53 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Total Operating Expenses of Shanghai Rendu Biotechnology Co is 85.03 M CNY in 2025.

Total Operating Expenses of Shanghai Rendu Biotechnology Co changed from 96.76 M CNY to 85.03 M CNY, representing a -12.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Shanghai Rendu Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co